1-17 of 17
Christopher P. Mill
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1227: Novel combination therapies to overcome non-genetic/adaptive menin inhibitor resistance in AML with MLL1r or mtNPM1

Warren C. Fiskus, Christopher P. Mill, Jessica Piel, Murphy Hentemann, Christine E. Birdwell, Kaberi Das, John A. Davis, Hanxi Hou, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Branko Cuglievan, Courtney D. DiNArdo, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1227.
https://doi.org/10.1158/1538-7445.AM2024-1227
Published: 22 March 2024
View article titled, Abstract 1227: Novel combination therapies to overcome non-genetic/adaptive menin inhibitor resistance in AML with MLL1r or mtNPM1
Journal Articles

Abstract 3044: Novel agents with efficacy against germline mutant RUNX1 familial platelet disorder with myeloid malignancy (FPD-MM)

Christopher P. Mill, Warren C. Fiskus, Courtney D. DiNardo, Patrick K. Reville, John A. Davis, Christine E. Birdwell, Kaberi Das, Hanxi Hou, Koichi Takahashi, Sanam Loghavi, Joseph D. Khoury, Kapil Bhalla
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3044.
https://doi.org/10.1158/1538-7445.AM2024-3044
Published: 22 March 2024
View article titled, Abstract 3044: Novel agents with efficacy against germline mutant RUNX1 familial platelet disorder with myeloid malignancy (FPD-MM)
Journal Articles

Abstract 3351: Identifying novel therapies from unbiased screens in AML with MECOM re-arrangement

Christine E. Birdwell, Warren C. Fiskus, Christopher P. Mill, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Koji Sasaki, John A. Davis, Kaberi Das, Hanxi Hou, Michele Cerebelli, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3351.
https://doi.org/10.1158/1538-7445.AM2024-3351
Published: 22 March 2024
View article titled, Abstract 3351: Identifying novel therapies from unbiased screens in AML with MECOM re-arrangement
Journal Articles

Abstract 1140: Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher P. Mill, Christine E. Birdwell, Kaberi Das, John A. Davis, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Courtney D. DiNardo, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1140.
https://doi.org/10.1158/1538-7445.AM2023-1140
Published: 04 April 2023
View article titled, Abstract 1140: Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML
Journal Articles

Abstract 4900: Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

Christine E. Birdwell, Warren C. Fiskus, Tapan M. Kadia, Christopher P. Mill, John A. Davis, Kaberi Das, Stephen Horrigan, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4900.
https://doi.org/10.1158/1538-7445.AM2023-4900
Published: 04 April 2023
View article titled, Abstract 4900: Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression
Journal Articles

Abstract 6285: Preclinical efficacy of CDK7 inhibitor-based combinations in cellular models of advanced myeloproliferative neoplasms (MPN)

Christopher P. Mill, Warren C. Fiskus, Christine E. Birdwell, John A. Davis, Kaberi Das, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6285.
https://doi.org/10.1158/1538-7445.AM2023-6285
Published: 04 April 2023
View article titled, Abstract 6285: Preclinical efficacy of CDK7 inhibitor-based combinations in cellular models of advanced myeloproliferative neoplasms (MPN)
Journal Articles

Abstract 4030: Efficacy of novel combination therapy against AML cells with mutant NPM1

Christopher P. Mill, Warren C. Fiskus, John A. Davis, Courtney D. DiNardo, Christine Birdwell, Qi Jin, Koichi Takahashi, Joseph D. Khoury, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4030.
https://doi.org/10.1158/1538-7445.AM2022-4030
Published: 15 June 2022
View article titled, Abstract 4030: Efficacy of novel combination therapy against AML cells with mutant NPM1
Journal Articles

Abstract 4028: Menin inhibitor-based combinations to improve efficacy and overcome resistance in AML

Warren C. Fiskus, Christopher P. Mill, Christine Birdwell, John A. Davis, Qi Jin, Tapan M. Kadia, Courtney D. DiNardo, Koichi Takahashi, Gerard M. McGeehan, Naval Daver, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4028.
https://doi.org/10.1158/1538-7445.AM2022-4028
Published: 15 June 2022
View article titled, Abstract 4028: Menin inhibitor-based combinations to improve efficacy and overcome resistance in AML
Journal Articles

Abstract 2648: Novel combination therapies against AML with 3q26 lesions and EVI1 overexpression

Christine Birdwell, Warren C. Fiskus, Christopher P. Mill, John A. Davis, Qi Jin, Courtney D. DiNardo, Koichi Takahashi, Stephen Horrigan, Tapan M. Kadia, Naval Daver, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2648.
https://doi.org/10.1158/1538-7445.AM2022-2648
Published: 15 June 2022
View article titled, Abstract 2648: Novel combination therapies against AML with 3q26 lesions and EVI1 overexpression
Journal Articles

Abstract 1071: Targeted therapy evaluation in novel pre-clinical in vitro and in vivo models of Richter transformation

Warren C. Fiskus, Abhishek Maiti, Dyana T. Saenz, Christopher P. Mill, Joseph D. Khoury, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1071.
https://doi.org/10.1158/1538-7445.AM2019-1071
Published: 01 July 2019
View article titled, Abstract 1071: Targeted therapy evaluation in novel pre-clinical <em>in vitro</em> and <em>in vivo</em> models of Richter transformation
Journal Articles

Abstract 3836: Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML

Dyana T. Saenz, Warren C. Fiskus, Taghi Manshouri, Christopher P. Mill, Joseph D. Khoury, Srdan Verstovsek, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3836.
https://doi.org/10.1158/1538-7445.AM2019-3836
Published: 01 July 2019
View article titled, Abstract 3836: Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML
Journal Articles

Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor

Dyana T. Saenz, Warren C. Fiskus, Taghi Manshouri, Christopher P. Mill, Steve Horrigan, Raffaella Soldi, Joseph D. Khoury, Sunil Sharma, Srdan Verstovesek, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3036.
https://doi.org/10.1158/1538-7445.AM2019-3036
Published: 01 July 2019
View article titled, Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor
Journal Articles

Abstract 802: Targeted inhibition of KDM1A and BET proteins or DNMT1 exerts synergistic lethal activity against human AML blast progenitor cells

Warren C. Fiskus, Christopher P. Mill, Dyana T. Saenz, Agnieszka J. Nowak, Baohua Sun, David N. Saenz, Steven M. Kornblau, Sunil Sharma, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 802.
https://doi.org/10.1158/1538-7445.AM2018-802
Published: 01 July 2018
View article titled, Abstract 802: Targeted inhibition of KDM1A and BET proteins or DNMT1 exerts synergistic lethal activity against human AML blast progenitor cells
Journal Articles

Abstract 3884: Novel RUNX1 targeted therapy for AML expressing mutant RUNX1

Christopher P. Mill, Courtney D. DiNardo, Warren Fiskus, Dyana T. Saenz, Agnieszka J. Nowak, Baohua Sun, David N. Saenz, Steven M. Kornblau, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3884.
https://doi.org/10.1158/1538-7445.AM2018-3884
Published: 01 July 2018
View article titled, Abstract 3884: Novel RUNX1 targeted therapy for AML expressing mutant RUNX1
Journal Articles

Abstract LB-081: Novel and effective RUNX1-targeted therapy for AML expressing RUNX1 mutation

Christopher P. Mill, Courtney DiNardo, Warren C. Fiskus, Dyana T. Saenz, Baohua Sun, Agnieszka J. Nowak, Misun Kim, Mark Routbort, Koichi Takahashi, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): LB-081.
https://doi.org/10.1158/1538-7445.AM2017-LB-081
Published: 01 July 2017
View article titled, Abstract LB-081: Novel and effective RUNX1-targeted therapy for AML expressing RUNX1 mutation
Journal Articles

Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

Dyana T. Saenz, Warren C. Fiskus, Kanak Raina, Taghi Manshouri, Kevin G. Coleman, Yimin Qian, Andrew P. Crew, Angela Shen, Christopher P. Mill, Baohua Sun, Misun Kim, Agnieszka J. Nowak, Srdan Verstovsek, Craig M. Crews, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5067.
https://doi.org/10.1158/1538-7445.AM2017-5067
Published: 01 July 2017
View article titled, Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
Journal Articles

SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents

Warren Fiskus, Veena Coothankandaswamy, Jianguang Chen, Hongwei Ma, Kyungsoo Ha, Dyana T. Saenz, Stephanie S. Krieger, Christopher P. Mill, Baohua Sun, Peng Huang, Jeffrey S. Mumm, Ari M. Melnick, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2016) 76 (18): 5467–5478.
https://doi.org/10.1158/0008-5472.CAN-16-0126
Published: 15 September 2016
View article titled, SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents
Open the PDF for SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents in another window
Includes: Supplementary data